- Home
- NTIP vs PLUR Comparison
NTIP vs PLUR Comparison
Compare NTIP & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- PLUR
- Stock Information
- Founded
- NTIP 1990
- PLUR 2001
- Country
- NTIP United States
- PLUR Israel
- Employees
- NTIP N/A
- PLUR N/A
- Industry
- NTIP Multi-Sector Companies
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIP Miscellaneous
- PLUR Health Care
- Exchange
- NTIP Nasdaq
- PLUR Nasdaq
- Market Cap
- NTIP 32.0M
- PLUR 36.9M
- IPO Year
- NTIP 1998
- PLUR N/A
- Fundamental
- Price
- NTIP $1.48
- PLUR $3.69
- Analyst Decision
- NTIP
- PLUR Strong Buy
- Analyst Count
- NTIP 0
- PLUR 1
- Target Price
- NTIP N/A
- PLUR $12.00
- AVG Volume (30 Days)
- NTIP 8.8K
- PLUR 9.2K
- Earning Date
- NTIP 10-24-2025
- PLUR 11-11-2025
- Dividend Yield
- NTIP 6.69%
- PLUR N/A
- EPS Growth
- NTIP N/A
- PLUR N/A
- EPS
- NTIP N/A
- PLUR N/A
- Revenue
- NTIP $150,000.00
- PLUR $1,336,000.00
- Revenue This Year
- NTIP N/A
- PLUR $97.38
- Revenue Next Year
- NTIP N/A
- PLUR $293.97
- P/E Ratio
- NTIP N/A
- PLUR N/A
- Revenue Growth
- NTIP N/A
- PLUR 309.82
- 52 Week Low
- NTIP $1.16
- PLUR $3.33
- 52 Week High
- NTIP $1.90
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- NTIP 44.83
- PLUR 37.09
- Support Level
- NTIP $1.48
- PLUR $3.60
- Resistance Level
- NTIP $1.58
- PLUR $4.00
- Average True Range (ATR)
- NTIP 0.05
- PLUR 0.18
- MACD
- NTIP -0.00
- PLUR -0.02
- Stochastic Oscillator
- NTIP 3.00
- PLUR 9.68
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.